Welcome to LookChem.com Sign In|Join Free

CAS

  • or
5-ANDROSTEN-3-BETA, 7-BETA-DIOL-17-ONE, also known as 7β-Hydroxydehydroepiandrosterone (7β-OH DHEA), is a white solid that serves as the main metabolite of Dehydroepiandrosterone (DHEA). It is a significant compound in the field of biochemistry and has various applications across different industries.

2487-48-1 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 2487-48-1 Structure
  • Basic information

    1. Product Name: 5-ANDROSTEN-3-BETA, 7-BETA-DIOL-17-ONE
    2. Synonyms: 5-ANDROSTEN-3-BETA, 7-BETA-DIOL-17-ONE;7-BETA-HYDROXYDEHYDROEPIANDROSTERONE;7 BETA-HYDROXY DHEA;ANDROST-5-EN-17-ONE, 3,7-DIHYDROXY-, (3BETA,7BETA)-;Androst-5-en-17-one, 3,7-dihydroxy-, (3beta,7beta)- (9CI);(3S,7R,8R,9S,10R,13S,14S)-3,7-dihydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one;7b-Hydroxydehydroepiandrosterone;3α,7β-Hydroxyandrost-5-en-17-one
    3. CAS NO:2487-48-1
    4. Molecular Formula: C19H28O3
    5. Molecular Weight: 304.42
    6. EINECS: N/A
    7. Product Categories: STEROID
    8. Mol File: 2487-48-1.mol
  • Chemical Properties

    1. Melting Point: 215-216 °C(Solv: acetone (67-64-1); cyclohexane (110-82-7))
    2. Boiling Point: 473.271 °C at 760 mmHg
    3. Flash Point: 254.138 °C
    4. Appearance: /
    5. Density: 1.194 g/cm3
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. PKA: 14.06±0.70(Predicted)
    10. CAS DataBase Reference: 5-ANDROSTEN-3-BETA, 7-BETA-DIOL-17-ONE(CAS DataBase Reference)
    11. NIST Chemistry Reference: 5-ANDROSTEN-3-BETA, 7-BETA-DIOL-17-ONE(2487-48-1)
    12. EPA Substance Registry System: 5-ANDROSTEN-3-BETA, 7-BETA-DIOL-17-ONE(2487-48-1)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 2487-48-1(Hazardous Substances Data)

2487-48-1 Usage

Uses

Used in Pharmaceutical Industry:
5-ANDROSTEN-3-BETA, 7-BETA-DIOL-17-ONE is used as an intermediate in the synthesis of various pharmaceutical compounds for [application reason]. Its role in the metabolism of DHEA makes it a crucial component in the development of drugs targeting hormonal imbalances and related health issues.
Used in Research and Development:
In the field of research and development, 5-ANDROSTEN-3-BETA, 7-BETA-DIOL-17-ONE is used as a key compound for studying the metabolic pathways of DHEA and its effects on the human body. This helps in understanding the underlying mechanisms of various hormonal disorders and the potential therapeutic applications of DHEA and its metabolites.
Used in Cosmetics Industry:
5-ANDROSTEN-3-BETA, 7-BETA-DIOL-17-ONE is used as an active ingredient in the cosmetics industry for [application reason]. Its presence in DHEA, which is known for its anti-aging properties, makes it a valuable component in the formulation of anti-aging and skin care products.
Used in Sports Nutrition:
5-ANDROSTEN-3-BETA, 7-BETA-DIOL-17-ONE is used as a performance-enhancing substance in the sports nutrition industry for [application reason]. Its connection to DHEA, which is known to improve muscle strength and endurance, makes it a popular choice among athletes looking to boost their performance.
Used in Hormone Replacement Therapy:
In the field of hormone replacement therapy, 5-ANDROSTEN-3-BETA, 7-BETA-DIOL-17-ONE is used as a precursor for the synthesis of hormones for [application reason]. Its role in the metabolism of DHEA allows for the development of targeted treatments for individuals experiencing hormonal imbalances or deficiencies.

Check Digit Verification of cas no

The CAS Registry Mumber 2487-48-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,4,8 and 7 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 2487-48:
(6*2)+(5*4)+(4*8)+(3*7)+(2*4)+(1*8)=101
101 % 10 = 1
So 2487-48-1 is a valid CAS Registry Number.

2487-48-1Synthetic route

7β-hydroxy-17-oxoandrost-5-ene-3β-yl acetate

7β-hydroxy-17-oxoandrost-5-ene-3β-yl acetate

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

Conditions
ConditionsYield
With sodium carbonate In methanol; water for 1.25h; Heating;83%
With water; sodium carbonate In methanol for 3h; Reflux;75%
dehydroepiandrosterone
53-43-0

dehydroepiandrosterone

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

Conditions
ConditionsYield
With Dipodia gossypina54%
mit Hilfe einer Rhizopus-Art;
With Botryodiplodia malorum In phosphate buffer; dimethyl sulfoxide at 30℃; for 72h; pH=6.0; Microbiological reaction;
dehydroepiandrosterone
53-43-0

dehydroepiandrosterone

A

5-androstene-3β-ol-7,17-dione
566-19-8

5-androstene-3β-ol-7,17-dione

B

3β,7α-dihydroxyandrost-5-ene-17-one
2487-48-1, 7522-54-5, 62357-03-3, 53-00-9

3β,7α-dihydroxyandrost-5-ene-17-one

C

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

Conditions
ConditionsYield
With Mortierella isabellina AM212 fungal strain for 12h; Enzymatic reaction;A 6%
B 53.5%
C 24%
With Absidia coerulea AM93 In acetone at 20℃; for 8h; Time; Enzymatic reaction;A 5.5%
B 22%
C 49%
dehydroepiandrosterone
53-43-0

dehydroepiandrosterone

A

3β,7α-dihydroxyandrost-5-ene-17-one
2487-48-1, 7522-54-5, 62357-03-3, 53-00-9

3β,7α-dihydroxyandrost-5-ene-17-one

B

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

Conditions
ConditionsYield
With Aspergillus wentii MRC 200316 In water; N,N-dimethyl-formamide at 27℃; for 120h; pH=7.2; Culture medium; Microbiological reaction; Enzymatic reaction;A 51%
B 12%
With dipotassium hydrogenphosphate; magnesium sulfate heptahydrate; Maltose for 96h; Enzymatic reaction;A 43.6%
B 12.6%
With Mucor racemosus In acetone at 27℃; for 96h;A 40.9%
B 18%
dehydroepiandrosterone
53-43-0

dehydroepiandrosterone

A

3β,7α-dihydroxyandrost-5-ene-17-one
2487-48-1, 7522-54-5, 62357-03-3, 53-00-9

3β,7α-dihydroxyandrost-5-ene-17-one

B

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

C

3β,5α,6β-trihydroxy-5α-androstan-17-one
10161-36-1

3β,5α,6β-trihydroxy-5α-androstan-17-one

D

3β,11α-dihydroxyandrost-5-en-17-one
39663-17-7

3β,11α-dihydroxyandrost-5-en-17-one

Conditions
ConditionsYield
With Cephalosporium aphidicola In ethanol; dimethyl sulfoxide for 192h;A 31%
B 25%
C 6%
D 6%
dehydroepiandrosterone
53-43-0

dehydroepiandrosterone

A

3β,7α-dihydroxyandrost-5-ene-17-one
2487-48-1, 7522-54-5, 62357-03-3, 53-00-9

3β,7α-dihydroxyandrost-5-ene-17-one

B

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

C

3β-hydroxy-13,17-secoandrost-5-ene-17,13α-lactone
2061-72-5

3β-hydroxy-13,17-secoandrost-5-ene-17,13α-lactone

D

testololactone
4416-57-3

testololactone

Conditions
ConditionsYield
With Aspergillus tamarii MRC 72400 In N,N-dimethyl-formamide at 25℃; for 120h; Baeyer-Villiger oxidation; Microbiological reaction;A 24%
B 13%
C 28%
D 6%
prasterone acetate
853-23-6

prasterone acetate

A

5-androstene-3β-ol-7,17-dione
566-19-8

5-androstene-3β-ol-7,17-dione

B

3β,7α-dihydroxyandrost-5-ene-17-one
2487-48-1, 7522-54-5, 62357-03-3, 53-00-9

3β,7α-dihydroxyandrost-5-ene-17-one

C

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

D

3β,14α-dihydroxyandrost-5-en-7,17-dione
58211-52-2

3β,14α-dihydroxyandrost-5-en-7,17-dione

Conditions
ConditionsYield
With Cunninghamella elegans In ethanol for 72h; Further byproducts given;A 5.4%
B 26.8%
C 9%
D 1.1%
With Cunninghamella elegans In ethanol for 72h; Further byproducts given;A 5.4%
B 26.8%
C 9%
D 1.1%
Benzoic acid (3S,7R,8R,9S,10R,13S,14S)-7-isobutyryloxy-10,13-dimethyl-17-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester
188176-04-7

Benzoic acid (3S,7R,8R,9S,10R,13S,14S)-7-isobutyryloxy-10,13-dimethyl-17-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

Conditions
ConditionsYield
With sodium hydroxide In tetrahydrofuran; methanol at 60℃; for 29h;26%
dehydroepiandrosterone
53-43-0

dehydroepiandrosterone

A

6α-hydroxy-androst-4-ene-3,17-dione
24704-84-5

6α-hydroxy-androst-4-ene-3,17-dione

B

5α-androst-3,6,17-trione
2243-05-2

5α-androst-3,6,17-trione

C

3β,7α-dihydroxyandrost-5-ene-17-one
2487-48-1, 7522-54-5, 62357-03-3, 53-00-9

3β,7α-dihydroxyandrost-5-ene-17-one

D

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

E

7α-hydroxyandrost-4-ene-3,17-dione
62-84-0, 31427-20-0

7α-hydroxyandrost-4-ene-3,17-dione

F

6β-hydroxy-4-androstene-3,17-dione
63-00-3

6β-hydroxy-4-androstene-3,17-dione

Conditions
ConditionsYield
With Cladosporium sphaerospermum MRC 70266 In water; N,N-dimethyl-formamide at 28℃; for 120h; Enzymatic reaction;A 5%
B 4%
C 20%
D 4%
E 6%
F 15%
dehydroepiandrosterone
53-43-0

dehydroepiandrosterone

A

5-androstene-3β-ol-7,17-dione
566-19-8

5-androstene-3β-ol-7,17-dione

B

3β,7α-dihydroxyandrost-5-ene-17-one
2487-48-1, 7522-54-5, 62357-03-3, 53-00-9

3β,7α-dihydroxyandrost-5-ene-17-one

C

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

D

3β,7β-dihydroxy-5β,6β-epoxyandrostan-17-one

3β,7β-dihydroxy-5β,6β-epoxyandrostan-17-one

E

3β,4β,7β-trihydroxyandrost-5-en-17-one

3β,4β,7β-trihydroxyandrost-5-en-17-one

F

3β,7α-dihydroxy-5β,6β-epoxyandrostan-17-one

3β,7α-dihydroxy-5β,6β-epoxyandrostan-17-one

G

3β,4β,7α-trihydroxyandrost-5-en-17-one

3β,4β,7α-trihydroxyandrost-5-en-17-one

Conditions
ConditionsYield
With Ulocladium chartarum MRC 72584 In water; N,N-dimethyl-formamide at 28℃; for 120h; Enzymatic reaction;A 6%
B 12%
C 16%
D 3%
E 4%
F 2%
G 3%
3α,5-cyclo-5α-androstan-6β-ol-17-one
663-39-8

3α,5-cyclo-5α-androstan-6β-ol-17-one

A

3β,7α-dihydroxyandrost-5-ene-17-one
2487-48-1, 7522-54-5, 62357-03-3, 53-00-9

3β,7α-dihydroxyandrost-5-ene-17-one

B

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

C

3β,14α-dihydroxy-androst-5-en-17-one
94991-86-3

3β,14α-dihydroxy-androst-5-en-17-one

D

14α-hydroxy-3α,5-cycloandrostane-6,17-dione

14α-hydroxy-3α,5-cycloandrostane-6,17-dione

Conditions
ConditionsYield
With culture of Cephalosporium aphidicola In ethanol; dimethyl sulfoxide for 192h; Oxidation; hydroxylation; rearrangement; biotransformation; Further byproducts given;A 15%
B 13%
C 6%
D 2%
3α,5-cyclo-5α-androstan-6β-ol-17-one
663-39-8

3α,5-cyclo-5α-androstan-6β-ol-17-one

A

3β,7α-dihydroxyandrost-5-ene-17-one
2487-48-1, 7522-54-5, 62357-03-3, 53-00-9

3β,7α-dihydroxyandrost-5-ene-17-one

B

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

C

3β,5α,6β-trihydroxy-5α-androstan-17-one
10161-36-1

3β,5α,6β-trihydroxy-5α-androstan-17-one

D

6β,14α-dihydroxy-3α,5-cycloandrostan-17-one
24357-28-6

6β,14α-dihydroxy-3α,5-cycloandrostan-17-one

Conditions
ConditionsYield
With culture of Cephalosporium aphidicola In ethanol; dimethyl sulfoxide for 192h; Oxidation; hydroxylation; rearrangement; biotransformation; Further byproducts given;A 15%
B 13%
C 9%
D 10%
Conditions
ConditionsYield
With dipotassium hydrogenphosphate; magnesium sulfate heptahydrate; Maltose for 96h; Enzymatic reaction;A 8.9%
B 11.1%
prasterone acetate
853-23-6

prasterone acetate

A

5-androstene-3β-ol-7,17-dione
566-19-8

5-androstene-3β-ol-7,17-dione

B

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

C

5,6β-epoxy-3β,12α-dihydroxy-5β-androstan-17-one
58324-06-4

5,6β-epoxy-3β,12α-dihydroxy-5β-androstan-17-one

D

3β,14α-dihydroxyandrost-5-en-7,17-dione
58211-52-2

3β,14α-dihydroxyandrost-5-en-7,17-dione

Conditions
ConditionsYield
With Cunninghamella elegans In ethanol for 72h; Further byproducts given;A 5.4%
B 9%
C 4.1%
D 1.1%
5-androsten-3β,7β-diol-17-one ethylene ketal 3-tert-butyldimethylsilyl ether
202415-78-9

5-androsten-3β,7β-diol-17-one ethylene ketal 3-tert-butyldimethylsilyl ether

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

Conditions
ConditionsYield
With hydrogenchloride In tetrahydrofuran; methanol
3β-acetoxy-20-hydroxyiminopregna-5,16-diene
23549-24-8, 23549-26-0, 2174-13-2

3β-acetoxy-20-hydroxyiminopregna-5,16-diene

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: POCl3; pyridine / toluene / 4 h / 10 - 20 °C
1.2: 51.8 percent / KOH / methanol / Heating
2.1: 18 percent / Mucor racemosus / acetone / 96 h / 27 °C
View Scheme
16-dehydropregnenolone acetate
979-02-2

16-dehydropregnenolone acetate

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: 87 percent / NH2OH*HCl / pyridine; ethanol; H2O / 0.5 h / Heating
2.1: POCl3; pyridine / toluene / 4 h / 10 - 20 °C
2.2: 51.8 percent / KOH / methanol / Heating
3.1: 18 percent / Mucor racemosus / acetone / 96 h / 27 °C
View Scheme
diosgenin
512-04-9

diosgenin

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: NH4Cl / pyridine / Heating
1.2: CrO3; CH3COOH / 1,2-dichloro-ethane / 0 °C
1.3: AcONa*3H2O / Heating
2.1: 87 percent / NH2OH*HCl / pyridine; ethanol; H2O / 0.5 h / Heating
3.1: POCl3; pyridine / toluene / 4 h / 10 - 20 °C
3.2: 51.8 percent / KOH / methanol / Heating
4.1: 18 percent / Mucor racemosus / acetone / 96 h / 27 °C
View Scheme
5-androsten-7,17-dione-3β-ol ethylene ketal tert-butyldimethylsilyl ether
202415-77-8

5-androsten-7,17-dione-3β-ol ethylene ketal tert-butyldimethylsilyl ether

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: NaBH4; CeCl3
2: HCl / methanol; tetrahydrofuran
View Scheme
3β-benzoyloxy-androst-5-en-17-one
83205-52-1, 2080-86-6

3β-benzoyloxy-androst-5-en-17-one

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

Conditions
ConditionsYield
Multi-step reaction with 8 steps
1: 91 percent / NaBH4 / CH2Cl2 / 2 h / 10 °C
2: 81 percent / pyridine / 48 h / Ambient temperature
3: 68 percent / CrO3, 3,5-dimethylpyrazole / CH2Cl2 / 3 h / -20 °C
4: 83 percent / CeCl3*5H2O, NaBH4 / tetrahydrofuran; methanol / 0.08 h
5: 90 percent / pyridine / 1 h / 0 °C
6: 36 percent / conc. HCl / CHCl3; methanol / 25 h / Ambient temperature
7: 93 percent / Jones reagent / acetone / 0.08 h / Ambient temperature
8: 26 percent / aq. NaOH / tetrahydrofuran; methanol / 29 h / 60 °C
View Scheme
Benzoic acid (3S,8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester
96073-67-5

Benzoic acid (3S,8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1: 81 percent / pyridine / 48 h / Ambient temperature
2: 68 percent / CrO3, 3,5-dimethylpyrazole / CH2Cl2 / 3 h / -20 °C
3: 83 percent / CeCl3*5H2O, NaBH4 / tetrahydrofuran; methanol / 0.08 h
4: 90 percent / pyridine / 1 h / 0 °C
5: 36 percent / conc. HCl / CHCl3; methanol / 25 h / Ambient temperature
6: 93 percent / Jones reagent / acetone / 0.08 h / Ambient temperature
7: 26 percent / aq. NaOH / tetrahydrofuran; methanol / 29 h / 60 °C
View Scheme
Benzoic acid (3S,8R,9S,10R,13S,14S,17S)-17-acetoxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester
188175-90-8

Benzoic acid (3S,8R,9S,10R,13S,14S,17S)-17-acetoxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: 68 percent / CrO3, 3,5-dimethylpyrazole / CH2Cl2 / 3 h / -20 °C
2: 83 percent / CeCl3*5H2O, NaBH4 / tetrahydrofuran; methanol / 0.08 h
3: 90 percent / pyridine / 1 h / 0 °C
4: 36 percent / conc. HCl / CHCl3; methanol / 25 h / Ambient temperature
5: 93 percent / Jones reagent / acetone / 0.08 h / Ambient temperature
6: 26 percent / aq. NaOH / tetrahydrofuran; methanol / 29 h / 60 °C
View Scheme
Benzoic acid (3S,7R,8R,9S,10R,13S,14S,17S)-17-acetoxy-7-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester
188176-01-4

Benzoic acid (3S,7R,8R,9S,10R,13S,14S,17S)-17-acetoxy-7-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 90 percent / pyridine / 1 h / 0 °C
2: 36 percent / conc. HCl / CHCl3; methanol / 25 h / Ambient temperature
3: 93 percent / Jones reagent / acetone / 0.08 h / Ambient temperature
4: 26 percent / aq. NaOH / tetrahydrofuran; methanol / 29 h / 60 °C
View Scheme
Benzoic acid (3S,7R,8R,9S,10R,13S,14S,17S)-17-hydroxy-7-isobutyryloxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester
188176-03-6

Benzoic acid (3S,7R,8R,9S,10R,13S,14S,17S)-17-hydroxy-7-isobutyryloxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 93 percent / Jones reagent / acetone / 0.08 h / Ambient temperature
2: 26 percent / aq. NaOH / tetrahydrofuran; methanol / 29 h / 60 °C
View Scheme
17β-acetoxy-3β-benzoyloxy-5-androsten-7-one
188176-00-3

17β-acetoxy-3β-benzoyloxy-5-androsten-7-one

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: 83 percent / CeCl3*5H2O, NaBH4 / tetrahydrofuran; methanol / 0.08 h
2: 90 percent / pyridine / 1 h / 0 °C
3: 36 percent / conc. HCl / CHCl3; methanol / 25 h / Ambient temperature
4: 93 percent / Jones reagent / acetone / 0.08 h / Ambient temperature
5: 26 percent / aq. NaOH / tetrahydrofuran; methanol / 29 h / 60 °C
View Scheme
Benzoic acid (3S,7R,8R,9S,10R,13S,14S,17S)-17-acetoxy-7-isobutyryloxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester
188176-02-5

Benzoic acid (3S,7R,8R,9S,10R,13S,14S,17S)-17-acetoxy-7-isobutyryloxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 36 percent / conc. HCl / CHCl3; methanol / 25 h / Ambient temperature
2: 93 percent / Jones reagent / acetone / 0.08 h / Ambient temperature
3: 26 percent / aq. NaOH / tetrahydrofuran; methanol / 29 h / 60 °C
View Scheme
3-O-acetyl-7-oxo-dehydroepiandrosterone
1449-61-2

3-O-acetyl-7-oxo-dehydroepiandrosterone

A

3β,7α-dihydroxyandrost-5-ene-17-one
2487-48-1, 7522-54-5, 62357-03-3, 53-00-9

3β,7α-dihydroxyandrost-5-ene-17-one

B

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

A

testosterone
58-22-0

testosterone

B

5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

C

Androst-5-ene-3beta,7alpha,17beta-triol
2697-85-0, 62357-04-4, 2226-66-6

Androst-5-ene-3beta,7alpha,17beta-triol

D

5-androstene-3β,7β,17β-triol
2697-85-0

5-androstene-3β,7β,17β-triol

Conditions
ConditionsYield
With water In ethanol for 120h; Microbiological reaction;
5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

1,1,1,3,3,3-hexamethyl-disilazane
999-97-3

1,1,1,3,3,3-hexamethyl-disilazane

3β,7β-bis-(trimethylsiloxy)-5-androsten-17-one
56210-85-6

3β,7β-bis-(trimethylsiloxy)-5-androsten-17-one

Conditions
ConditionsYield
saccharin In acetonitrile for 8h; Reflux; Inert atmosphere; Industry scale;81%
saccharin In acetonitrile for 8h; Reflux; Inert atmosphere;81%
5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

3β,7β-diacetoxyandrost-5-en-17-one
67576-47-0

3β,7β-diacetoxyandrost-5-en-17-one

C24H32O3

C24H32O3

Conditions
ConditionsYield
With scandium tris(trifluoromethanesulfonate) In acetonitrile78%
5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

3β,7β,11α-trihydroxy-5-androsten-17-one
537718-07-3

3β,7β,11α-trihydroxy-5-androsten-17-one

Conditions
ConditionsYield
With Apergillus ochraceus75%
With Aspergillus ochraceus ATCC 18500 (NRRL 405) Microbiological reaction;
5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

N-methoxylamine hydrochloride
593-56-6

N-methoxylamine hydrochloride

dimethylisopropylsilylimidazole
81452-04-2

dimethylisopropylsilylimidazole

(3S,7R,8R,9S,10R,13S,14S)-7-Hydroxy-3-(isopropyl-dimethyl-silanyloxy)-10,13-dimethyl-1,2,3,4,7,8,9,10,11,12,13,14,15,16-tetradecahydro-cyclopenta[a]phenanthren-17-one O-methyl-oxime

(3S,7R,8R,9S,10R,13S,14S)-7-Hydroxy-3-(isopropyl-dimethyl-silanyloxy)-10,13-dimethyl-1,2,3,4,7,8,9,10,11,12,13,14,15,16-tetradecahydro-cyclopenta[a]phenanthren-17-one O-methyl-oxime

Conditions
ConditionsYield
Stage #1: 5-androsten-3β,7β-diol-17-one; N-methoxylamine hydrochloride In pyridine at 60℃; for 1h;
Stage #2: dimethylisopropylsilylimidazole In pyridine at 60℃; for 0.5h;
5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

N-methoxylamine hydrochloride
593-56-6

N-methoxylamine hydrochloride

N-dimethylethylsilyl-imidazole
62365-34-8

N-dimethylethylsilyl-imidazole

(3S,7R,8R,9S,10R,13S,14S)-3-(Ethyl-dimethyl-silanyloxy)-7-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,10,11,12,13,14,15,16-tetradecahydro-cyclopenta[a]phenanthren-17-one O-methyl-oxime

(3S,7R,8R,9S,10R,13S,14S)-3-(Ethyl-dimethyl-silanyloxy)-7-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,10,11,12,13,14,15,16-tetradecahydro-cyclopenta[a]phenanthren-17-one O-methyl-oxime

Conditions
ConditionsYield
Stage #1: 5-androsten-3β,7β-diol-17-one; N-methoxylamine hydrochloride In pyridine at 60℃; for 1h;
Stage #2: N-dimethylethylsilyl-imidazole In pyridine at 60℃; for 0.5h;
5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

N-methoxylamine hydrochloride
593-56-6

N-methoxylamine hydrochloride

1-(Trimethylsilyl)imidazole
18156-74-6

1-(Trimethylsilyl)imidazole

(3S,7R,8R,9S,10R,13S,14S)-7-Hydroxy-10,13-dimethyl-3-trimethylsilanyloxy-1,2,3,4,7,8,9,10,11,12,13,14,15,16-tetradecahydro-cyclopenta[a]phenanthren-17-one O-methyl-oxime

(3S,7R,8R,9S,10R,13S,14S)-7-Hydroxy-10,13-dimethyl-3-trimethylsilanyloxy-1,2,3,4,7,8,9,10,11,12,13,14,15,16-tetradecahydro-cyclopenta[a]phenanthren-17-one O-methyl-oxime

Conditions
ConditionsYield
Stage #1: 5-androsten-3β,7β-diol-17-one; N-methoxylamine hydrochloride In pyridine at 60℃; for 1h;
Stage #2: 1-(Trimethylsilyl)imidazole In pyridine at 60℃; for 0.5h;
5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

(1S,2S,4aS,4bR,7S,10R,10aR)-1-Carboxymethyl-7,10-dihydroxy-2,4b-dimethyl-1,2,3,4,4a,4b,5,6,7,8,10,10a-dodecahydro-phenanthrene-2-carboxylic acid

(1S,2S,4aS,4bR,7S,10R,10aR)-1-Carboxymethyl-7,10-dihydroxy-2,4b-dimethyl-1,2,3,4,4a,4b,5,6,7,8,10,10a-dodecahydro-phenanthrene-2-carboxylic acid

Conditions
ConditionsYield
With potassium hydroxide; iodine In methanol; water at 20℃; for 16h;
5-androsten-3β,7β-diol-17-one
2487-48-1

5-androsten-3β,7β-diol-17-one

tert-butyldimethylsilyl chloride
18162-48-6

tert-butyldimethylsilyl chloride

C31H56O3Si2
1016226-91-7

C31H56O3Si2

Conditions
ConditionsYield
With 1H-imidazole In N,N-dimethyl-formamide at 20℃;

2487-48-1Relevant articles and documents

Biotransformation of 5-en-3β-ol steroids by Mucor circinelloides lusitanicus

Shan, Lihong,Jiao, Kai,Yin, Minghui,Huang, Jiajia,Chen, Yanjie,Qin, Shangshang,Liu, Hongmin

, p. 83 - 88 (2016)

In this work, we report the mode of biotransformation of 5-en-3β-ol steroids using Mucor circinelloides lusitanicus for the first time. Here, we selected seven 5-en-3β-ol steroids as substrates. The main characteristic of the fungus was to introduce a 7α-hydroxyl group into substrates 1--5. With substrate 2, 3β, 7α, 11α-trihydroxypregna-5-en-20-one (2b) was obtained as the final product in good yield (46.4%). All the metabolites were determined by infrared spectra, high-resolution mass spectrometry, proton nuclear magnetic resonance, and carbon-13 nuclear magnetic resonance.

Steroid hydroxylations with Botryodiplodia malorum and Colletotrichum lini

Romano, Andrea,Romano, Diego,Ragg, Enzio,Costantino, Francesca,Lenna, Roberto,Gandolfi, Raffaella,Molinari, Francesco

, p. 429 - 434 (2006)

An improved procedure for the microbial hydroxylations of dehydroepiandrosterone (DHEA, 1) and 15β,16β-methylene-dehydroepiandrosterone (2) was studied using whole cells of Botryodiplodia malorum and Colletotrichum lini. C. lini catalyzed 7α- and 15α-hydroxylation of 1 and 7α-hydroxylation of 2, while B. malorum gave 7β-hydroxylation of both the substrates. The stability of the enzymatic activity was higher in the presence of co-substrates (i.e., glucose or mannitol) allowing for repeated batches of the biotransformations. The yields of 7α,15α-dihydroxy-1 production were improved obtaining 5.8 g l-1 (recovered product) from 7.0 g l-1 of substrate. The structures of the hydroxylated products were assigned by a combination of two-dimensional NMR proton-proton and proton-carbon correlation techniques.

Anti-proliferative action of endogenous dehydroepiandrosterone metabolites on human cancer cell lines.

Yoshida, Shigemasa,Honda, Akira,Matsuzaki, Yasushi,Fukushima, Sugano,Tanaka, Naomi,Takagiwa, Aya,Fujimoto, Yoshinori,Miyazaki, Hiroshi,Salen, Gerald

, p. 73 - 83 (2003)

Dehydroepiandrosterone (DHEA) is a naturally occurring steroid synthesized in the adrenal cortex, gonads, brain, and gastrointestinal tract, and it is known to have chemopreventive and anti-proliferative actions on tumors. These effects are considered to be induced by the inhibition of glucose-6-phosphate dehydrogenase (G6PD) and/or HMG-CoA reductase (HMGR) activities. The present study was undertaken to investigate whether endogenous DHEA metabolites, i.e. DHEA-sulfate, 7-oxygenated DHEA derivatives, androsterone, epiandrosterone, and etiocholanolone, have anti-proliferative effects on cancer cells and to clarify which enzyme, G6PD or HMGR, is responsible for growth inhibition. Growth of Hep G2, Caco-2, and HT-29 cells, evaluated by 3-[4,5-dimethylthiazol]-2yl-2,5-diphenyl tetrazolium bromide (MTT) and bromodeoxyuridine incorporation assays, was time- and dose-dependently inhibited by addition of all DHEA-related steroids we tested. In particular, the growth inhibition due to etiocholanolone was considerably greater than that caused by DHEA in all cell lines. The suppression of growth of the incubated steroids was not correlated with the inhibition of G6PD (r=-0.031, n=9, NS) or HMGR (r=0.219, n=9, NS) activities. The addition of deoxyribonucleosides or mevalonolactone to the medium did not overcome the inhibition of growth induced by DHEA or etiocholanolone, while growth suppression by DHEA was partially prevented by the addition of ribonucleosides. These results demonstrate that endogenous DHEA metabolites also have an anti-proliferative action that is not induced by inhibiting G6PD or HMGR activity alone. These non-androgenic DHEA metabolites may serve as chemopreventive or anti-proliferative therapies.

Enhancement of steroid hydroxylation yield from dehydroepiandrosterone by cyclodextrin complexation technique

Wu, Yan,Li, Hui,Lu, Zhen-Ming,Li, Heng,Rao, Zhi-Ming,Geng, Yan,Shi, Jin-Song,Xu, Zheng-Hong

, p. 70 - 77 (2014)

The cyclodextrins (CDs) complexation technique was performed for the enhancement of hydroxylation yield from dehydroepiandrosterone (DHEA) by Colletotrichum lini ST-1. Using DHEA/methyl-β-cyclodextrin (M-β-CD) or DHEA/hydroxypropyl-β-cyclodextrin (HP-β-CD) inclusion complexes as substrate (10 g/L), the hydroxylation yields were increased by 14.98% and 20.54% respectively, and the biotransformation course was shortened by 12 h. X-ray diffractometry, differential scanning calorimetry, and phase solubility analyses showed an inclusion complex was formed between CDs and DHEA at a molar ratio of 1:1, which remarkably increased the solubility of DHEA, and then improved substrate biotransformation efficiency and hydroxylation yield. Meanwhile, results of thermodynamic parameters (ΔG, ΔH, ΔS and Ks) analysis revealed the complexation process was spontaneous and DHEA/CDs inclusion complex was stable. Scanning electron microscopy and transmission electron microscopy showed that the enhancement of DHEA hydroxylation yield also depended on the improvement of cell permeability through interaction between cytomembrane and CDs. These results suggested that the CDs complexation technique was a promising method to enhance steroids hydroxylation yield by increasing steroids solubility and decreasing membrane resistance of substrate and product during biotransformation process.

Microbial transformation of dehydroepiandrosterone (DHEA) by some fungi

Yildirim, Kudret,Kuru, Ali,Y?lmazer Keskin, Semra,Ergin, Sinan

, p. 465 - 474 (2020/11/12)

In this work, biotransformations of dehydroepiandrosterone (DHEA) 1 by Ulocladium chartarum MRC 72584, Cladosporium sphaerospermum MRC 70266 and Cladosporium cladosporioides MRC 70282 have been reported. U. chartarum MRC 72584 mainly hydroxylated 1 at C-7α and C-7β, accompanied by a minor hydroxylation at C-4β, a minor epoxidation from the β-face and a minor oxidation at C-7 subsequent to its hydroxylations. 3β,7β-Dihydroxy-5β,6β-epoxyandrostan-17-one 6, 3β,4β,7α-trihydroxyandrost-5-en-17-one 7 and 3β,4β,7β-trihydroxyandrost-5-en-17-one 8 from this incubation were identified as new metabolites. C. sphaerospermum MRC 70266 converted some of 1 into a 3-keto-4-ene steroid and then hydroxylated at C-6α, C-6β and C-7α, accompanied a minor 5α-reduction and a minor oxidation at C-6 following its hydroxylations. C. sphaerospermum MRC 70266 also hydroxylated some of 1 at C-7α and C-7β. C. cladosporioides MRC 70282 converted almost half of 1 into a 3-keto-4-ene steroid and then hydroxylated at C-6α and C-6β. C. cladosporioides MRC 70282 also reduced some of 1 at C-17.

Oxidative Diversification of Steroids by Nature-Inspired Scanning Glycine Mutagenesis of P450BM3 (CYP102A1)

Cao, Yang,Chen, Wenyu,Fisher, Matthew J.,Leung, Aaron,Wong, Luet L.

, p. 8334 - 8343 (2020/09/18)

Steroidal compounds are some of the most prescribed medicines, being indicated for the treatment of a variety of conditions including inflammation, heart disease, and cancer. Synthetic approaches to functionalized steroids are important for generating steroidal agents for drug screening and development. However, chemical activation is challenging because of the predominance of inert, aliphatic C-H bonds in steroids. Here, we report the engineering of the stable, highly active bacterial cytochrome P450 enzyme P450BM3 (CYP102A1) from Bacillus megaterium for the mono- and dihydroxylation of androstenedione (AD), dehydroepiandrosterone (DHEA), and testosterone (TST). In order to design altered steroid binding orientations, we compared the structure of wild type P450BM3 with the steroid C19-demethylase CYP19A1 with AD bound within its active site and identified regions of the I helix and the β4 strand that blocked this binding orientation in P450BM3. Scanning glycine mutagenesis across 11 residues in these two regions led to steroid oxidation products not previously reported for P450BM3. Combining these glycine mutations in a second round of mutagenesis led to a small library of P450BM3 variants capable of selective (up to 97%) oxidation of AD, DHEA, and TST at the widest range of positions (C1, C2, C6, C7, C15, and C16) by a bacterial P450 enzyme. Computational docking of these steroids into molecular dynamics simulated structures of selective P450BM3 variants suggested crucial roles of glycine mutations in enabling different binding orientations from the wild type, including one that closely resembled that of AD in CYP19A1, while other mutations fine-tuned the product selectivity. This approach of designing mutations by taking inspiration from nature can be applied to other substrates and enzymes for the synthesis of natural products and their derivatives.

The generation of a steroid library using filamentous fungi immobilized in calcium alginate Dedicated to the memory of Professor Sir John W. Cornforth, University of Sussex (1917-2013).

Peart, Patrice C.,Reynolds, William F.,Reese, Paul B.

, p. 16 - 24 (2016/01/25)

Four fungi, namely, Rhizopus oryzae ATCC 11145, Mucor plumbeus ATCC 4740, Cunninghamella echinulata var. elegans ATCC 8688a, and Whetzelinia sclerotiorum ATCC 18687, were subjected to entrapment in calcium alginate, and the beads derived were used in the biotransformation of the steroids 3β,17β-dihydroxyandrost-5-ene (1) and 17β-hydroxyandrost-4-en-3-one (2). Incubations performed utilized beads from two different encapsulated fungi to explore their potential for the production of metabolites other than those derived from the individual fungi. The investigation showed that steroids from both single and crossover transformations were typically produced, some of which were hitherto unreported. The results indicated that this general technique can be exploited for the production of small libraries of compounds.

Hydroxylation of DHEA and its analogues by Absidia coerulea AM93. Can an inducible microbial hydroxylase catalyze 7α- and 7β-hydroxylation of 5-ene and 5α-dihydro C19-steroids?

Milecka-Tronina, Natalia,Ko?ek, Teresa,?wizdor, Alina,Panek, Anna

, p. 883 - 891 (2014/01/23)

In this paper we focus on the course of 7-hydroxylation of DHEA, androstenediol, epiandrosterone, and 5α-androstan-3,17-dione by Absidia coerulea AM93. Apart from that, we present a tentative analysis of the hydroxylation of steroids in A. coerulea AM93. DHEA and androstenediol were transformed to the mixture of allyl 7-hydroxy derivatives, while EpiA and 5α-androstan-3,17-dione were converted mainly to 7α- and 7β-alcohols accompanied by 9α- and 11α-hydroxy derivatives. On the basis of (i) time course analysis of hydroxylation of the abovementioned substrates, (ii) biotransformation with resting cells at different pH, (iii) enzyme inhibition analysis together with (iv) geometrical relationship between the C-H bond of the substrate undergoing hydroxylation and the cofactor-bound activated oxygen atom, it is postulated that the same enzyme can catalyze the oxidation of C7-Hα as well as C7-H β bonds in 5-ene and 5α-dihydro C19-steroids. Correlations observed between the structure of the substrate and the regioselectivity of hydroxylation suggest that 7β-hydroxylation may occur in the normal binding enzyme-substrate complex, while 7α-hydroxylation - in the reverse inverted binding complex.

Potential of Azadirachta indica cell suspension culture to produce biologically active metabolites of dehydroepiandrosterone

Saifullah,Khan, Saifullah,Azizuddin,Choudhary, Muhammad Iqbal

, p. 671 - 676 (2013/11/06)

Dehydroepiandrosterone (1) was investigated for biotransformation studies using the plant cell suspension culture of Azadirachta indica A. Juss. for the first time, yielding metabolites 2-6: 5α,3,17-androstanedione (2), 5-androstene-3β,17β-diol (3), 3β-hydroxyandrostan-17-one (4), 3β,11α-dihydroxy-5-androsten-17-one (5), and 3β,7α- dihydroxy-5-androsten-17-one (6), whose structures were solved through modern spectroscopic methods. All five compounds 2-6 have not been reported obtained by this way before. This is a new method to biosynthesize compounds 2-6 employing cultured cells of A. indica. Metabolites 2, 3, and 6 are important biologically active compounds, whereas 4 is a precursor for the production of the 7-hydroxylated compound having antiglucocorticoid and neuroprotective effects.

Biotransformation of some steroids by Mucor hiemalis MRC 70325

Yildirim, Kudret,Saran, Hilal,Dolu, Omer Faruk,Kuru, Ali

, p. 566 - 569 (2013/10/22)

In this work, incubations of testosterone, dehydroepiandrosterone and pregnenolone with Mucor hiemalis MRC 70325 have been reported. Incubation of testosterone afforded androst-4-en-3,17-dione (3%), 14a-hydroxyandrost- 4-en-3,17-dione (9%), 6β-hydroxyandrost-4-en-3,17-dione (2%) and 14a,17β-dihydroxyandrost-4-en-3-one (62%). Incubation of dehy droepiandrosterone afforded 3β,17β-dihydroxyandrost-5-ene (6%) and 3β,7α-dihydroxyandrost-5- en-17-one (72%). Incubation of pregnenolone afforded 3β,14a-dihydroxypregn-5-en-7,20-dione (3%), 3β,7α- dihydroxypregn- 5-en-20-one (64%) and 3β,7α,11α- trihydroxypregn-5-en-20-one (11%). 3β,14a-Dihydroxypregn-5-en-7,20-dione was identified as a new metabolite. Website

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 2487-48-1